New Agents for Treating Hyperkalemia - Can They Help Us Improve Outcomes in HF?

Similar documents
Managing the Yin and Yang of Hyperkalemia and MRAs in Heart Failure

New Approaches for Treating Hyperkalemia: Why, When and How?

Conflict of interest

Potassium as a Treatable Biomarker in Cardiovascular Disease: New Keys to Hyperkalemia

Treating HF Patients with ARNI s Why, When and How?

Hello, and thank you for joining us for this presentation on novel approaches to understanding risks and treatment of hyperkalemia.

Challenges in RAASi optimization: Hyperkalemia Management Bertram Pitt, M.D.* University of Michigan School of Medicine

Hyperkalemia a silent killer? PD Dr. med. Andreas Kistler Kantonsspital Frauenfeld

Cardiovascular Pharmacotherapy for Heart Failure Management

Faculty. Therapeutic Advances in Hyperkalemia. Disclosures. Learning Objectives 9/7/2018. A Pharmacist s Guide to Patient Identification and Treatment

PP-US-DSE Relypsa, Inc. All rights reserved. Relypsa and the Relypsa logo are trademarks of Relypsa, Inc.

VELTASSA (patiromer) oral suspension

Lokelma (sodium zirconium cyclosilicate), Veltassa (patiromer)

SUPPLEMENT TO FIRST REPORT

Congestive Heart Failure: Outpatient Management

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE

DECLARATION OF CONFLICT OF INTEREST

HYPERKALEMIA. Best Practices in Managing. in Chronic Kidney Disease

Giovambattista Desideri UO Geriatria Università dell Aquila. Iperkaliema e sideropenia nello scompenso cardiaco

Clinical Pearls in Renal Medicine

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Développement clinique du Patiromer et futures perspectives

HFpEF, Mito or Realidad?

LOKELMA (sodium zirconium cyclosilicate) oral suspension

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Antialdosterone treatment in heart failure

Jo Abraham MD Division of Nephrology University of Utah

Bruce Spinowitz, M.D. FACP

Combination of renin-angiotensinaldosterone. how to choose?

Updates in Heart Failure (HF) 2016: ACC / AHA and ESC

2017 Summer MAOFP Update

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin- Aldosterone System Inhibitors

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

OTE. Lokelma (sodium zirconium cyclosilicate): A Novel Agent for Chronic Hyperkalemia. Personalized Medicine Corner: Incorporating Pharmacogenetics

OPTIMISING RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR THERAPY IN HEART FAILURE AND RESISTANT HYPERTENSION: CHALLENGES AND SOLUTIONS

Drugs acting on the reninangiotensin-aldosterone

InformRx. Managing Chronic Hyperkalemia. By Pam Scandrett, R.Ph. Risks of High Potassium Levels CLINICAL & REGULATORY NEWS BY PHARMERICA

Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed

Heart Failure: Combination Treatment Strategies

Virtual Mentor American Medical Association Journal of Ethics April 2007, Volume 9, Number 4:

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation

Dosing Information. The First & Only FDA-approved Spironolactone Oral Suspension P HARM A. Exclusively from

REVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2

Faiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

HEART FAILURE: PHARMACOTHERAPY UPDATE

The ACC Heart Failure Guidelines

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition

The Failing Heart in Primary Care

New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure

CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR

Initiating New Medications in the Management of Heart Failure

Heart Failure Therapies State of the Art 2017

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

2016 Update to Heart Failure Clinical Practice Guidelines

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration

Tuesday October 18, :00pm 2:00pm Central Presenter: Clyde W. Yancy, MD, MSc

Long-Term Care Updates

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care

9/10/ , American Heart Association 2

Treatment guidelines recommend the use of renin

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure

Disclosures for Presenter

Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events

Contemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium

Heart Failure Pharmacotherapy An Update

Heart Failure: Guideline-Directed Management and Therapy

Heart Failure Update. Bibiana Cujec MD May 2015

Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management

SUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA

The P&T Committee Lisinopril (Qbrelis )

I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists

Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In?

Summary/Key Points Introduction

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?

eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd

ACE inhibitors: still the gold standard?

Recognizing and Treating Patients with the Cardio-Renal Syndrome

Disclaimer Usage Rights:

HFpEF. April 26, 2018

Heart Failure Clinician Guide JANUARY 2018

Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients

Heart Failure and Renal Disease Cardiorenal Syndrome

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA

Heart Failure: Current Management Strategies

4/26/2016. Chronic Kidney Disease for PCPs CLAIRE KASSAKIAN, MD NORTHWEST RENAL CLINIC ANNUAL PRACTICAL ADVANCES IN IM SYMPOSIUM

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

New Drugs for the Primary Care Provider: What You Need to Know

Transcription:

New Agents for Treating Hyperkalemia - Can They Help Us Improve Outcomes in HF? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor of Medicine Director, Advanced Heart Failure Treatement Program University of California, San Diego La Jolla, CA

ACC/AHA Guideline Recommendations for Treating Stage C HFrEF HFrEF Stage C NYHA Class I IV Treatment: Class I, LOE A ACEI or ARB AND Beta Blocker For all volume overload, NYHA class II-IV patients For persistently symptomatic African Americans, NYHA class III-IV For NYHA class II-IV patients. Provided estimated creatinine >30 ml/min and K+ <5.0 meq/dl Add Add Add Class I, LOE C Loop Diuretics Class I, LOE A Hydral-Nitrates Class I, LOE A Aldosterone Antagonist Yancy C et al, Circulation 2013

Trials With Mineralicorticoid Receptor Antagonists Primary Endpoint: All-Cause Mortality Trial Placebo Aldosterone Hazard Log-rank Antagonist Ratio P Value EPHESUS Post-MI RALES Advanced HF 554/3,319 478/3,313.85 (.75,.96).008 386/841 284/822.70 <.001 (.60,.82) EMPHASIS Milder HF 356/1373 249/1364.76 (.62,.93).008 Pitt B. N Engl J Med. 2003;348:1309-1321. Pitt B. N Engl J Med. 1999;341:709-717. Zannad F, et al. N Engl J Med. 2011;364:11-21

Hyperkalemia and the RALES Study Publication of RALES sparked an increase in prescriptions for spironolactone Also a parallel increase in hospital admissions and death from hyperkalemia Spironolactone prescription rate (per 1000 patients) Rate of admission for hyperkalemia (per 1000 patients) 160 140 120 100 80 60 40 20 0 12 10 8 6 4 2 0 Online release of RALES 1994 1996 1998 1999 2000 2001 Study year Online release of RALES 1994 1996 1998 1999 2000 2001 Study year Adapted from: Juurlink DN, et al. N Engl J Med. 2004;351:543-551.

The Addition of MRA to RAS Therapy Increases Hyperkalemia ( 6.0) Risk in HF Patients Hyperkalemia with spironolactone in Real-world vs Clinical-trial HF patients 14 12 Clinical trials Real-world 12 % of Patients 10 8 6 4 2 2 2.5 6 0 RALES EMPHASIS Shah 2005 Bozkurt 2003 1 2 3 4 N=822 N=1,336 N=840 N=104 1. Pitt B, Zannad F, Remme WJ, et al. N Engl J Med. 1999;341(10):709-717. 2. Zannad F. N Engl J Med. 2011;364:11-21. 3. Shah KB, et al. J Am Coll Cardiol. 2005;46(5):845-849. 4. Bozkurt B, et al. J Am Coll Cardiol. 2003;41(2):211-214.

Use of GDMT in HFrEF Results of the CHAMP-HF Registry

Hyperkalemia Was Common in PARADIGM-HF Patients Excluded Due to Elevated K + Levels During Run-in Period Veils Number of Patients with Elevated K + Due to Treatment McMurray et al., NEJM. 2014.

Hyperkalemia Is a Major Reason for MRA Discontinuation 134 HF patients followed in a Portuguese HF clinic Spironolactone use in patients with scr 2.5 mg/dl and K + 5 meq/l 25% of patients withdrew from spironolactone therapy (19/76) 30 Reason for spironolactone suspension (%) Hyperkalemia Renal function decline Gynecomastia Other % of Patients 20 10 17.1 0 Discontinuation DC of MRA of MRA *Severe hyperkalemia ( 6 meq/l) occurred in 7 patients who withdrew from spironolactone therapy (9.2%). Lopes RJ, et al. Clin Cardiol. 2008; 31:509-513.

Admitted 2011-2013 with Worsening of Chronic HF (n=1250) <1 Year Follow Up (n=806) >1 year Follow-Up (n=444) Not Candidates for MRA Based on Inclusion/ Exclusion Criteria (n=173) Discharged without MRA (n=164) Fulfilled Criteria for MRA Use (n=271) Only 105 of 271 (39%) Eligible Patients Were Taking an MRA on Admission MRA at Hospital Discharge (n=61) No MRA on Admission (n=210) MRA Initiated at DC (n=46) MRA Maintained during Hospitalization (n=59) MRA Discontinued (n=2) Receiving an MRA at Time of Hospital Discharge (n=105)

A (+) ON MRA (n=70) DC with MRA (n=105) (-) OFF MRA (n=35) (+) ON MRA (n = 70) MRA Tx to discharge, LVAD or OHT Without interruption With 1 or fewer drug discontinuations and tolerated therapy for > 180 days (6 months) 15 10 5 0 All-Cause Hospitalizations p = 0.0010 + - 10 8 6 4 2 0 Cardiovascular Hospitalizations p = 0.0032 + - (-) OFF MRA (n = 35) 2 or more discontinuations 1 discontinuation without restart and tx duration < 180 days (6 months) 8 6 4 2 0 Heart Failure Hospitalizations p = 0.0019 + - (+) ON MRA (-) OFF MRA Episodes of Hyperkalemia/Patient 2.5 2.0 1.5 1.0 0.5 0.0 p = 0.0006 + - Percent Survival (%) 100 50 Survival p < 0.02 0 0 500 1000 1500 2000 Days (+) ON MRA (-) OFF MRA

A (+) ON MRA (n=70) DC with MRA (n=105) (-) OFF MRA (n=35) (+) ON MRA (n = 70) MRA Tx to discharge, LVAD or OHT Without interruption With 1 or fewer drug discontinuations and tolerated therapy for > 180 days (6 months) All-Cause Hospitalizations 15 10 5 0 6 4 2 0 (-) OFF MRA (n = 35) 2 or more discontinuations 1 discontinuation without restart and tx duration < 180 days (6 months) Stopping an MRA is associated with worse outcomes 10 8 p including = 0.0010 increased p = 0.0032 mortality 8 6 + - Cardiovascular Hospitalizations + - 4 2 0 Heart Failure Hospitalizations p = 0.0019 + - (+) ON MRA (-) OFF MRA Episodes of Hyperkalemia/Patient 2.5 2.0 1.5 1.0 0.5 0.0 p = 0.0006 + - Percent Survival (%) 100 50 p < 0.02 Survival 0 0 500 1000 1500 2000 Days (+) ON MRA (-) OFF MRA

Association Between Renal Function and Hyperkalemia in HF Patients Shah KB et al, JCF Volume 46, Issue 5, 2005, 845 849

Drug-Induced Hyperkalemia Medications Associated with Hyperkalemia ACEi s, ARB s and sacubitril-valsartan combination K + -sparing diuretics, spironolactone Bactrim (trimethoprim), pentamidine NSAIDs Beta blocker (both non-selective and B2 selective) Heparin Digoxin (supratherapetuic levels) Succinylcholine (intubation in ICU, Surgery)* Calcineurin inhibitors (cyclosporine, tacrolimus [FK506]) Modified from Palmer BF. N Engl J Med. 2004;351(6):585-59

Long-Term Hyperkalemia Management Strategies Strategy Limitation Dietary K + restriction of 40-60 mmol/day Potassium is common ingredient in many foods Restricts consumption of healthy foods Low K + diet often expensive Kayexalate RAASi reduction Warnings related to serious gastrointestinal (GI) adverse events Precaution related to sodium Limiting the prescription of drugs known to be effective in these populations

Low K+ Diet Is the First Step in Chronic Management, but Compliance Is Difficult PotassiumRich Foods

KAYEXALATE (Sodium Polystyrene Sulfonate) Is Not the Answer Can cause colonic necrosis (particularly when used with sorbitol). Should not be used in patients who do not have normal bowel function or in patients who are at risk of developing constipation or impaction. Administration presents patient with obligatory salt and water load (e.g. each g of SPS contains 100 mg of Na+ and the average daily dose of SPS is 15-60 g/day. FDA: Food and Drug Administration References: http://www.fda.gov/safety/medwatch/safetyinformation/ucm186845.htm accessed 12/10/2014 Kayexalate PI December 2010. Sterns 2010; J Am Soc Nephrol 21: 733 735, 2010.; Kayexalate is a registered trademark of Sanofi Aventis

Changes in RAAS Inhibitor Dose In Response to Hyperkalemia Among Patients on RAAS Inhibitor at Maximum Dose Percent of Hyperkalemia Events 75% 60% 45% 30% 15% 0% Maintained Dose Down-titrated Dose Discontinued 52% 38% 22% 16% Mild Hyperkalemia (Potassium 5.1-5.4 meq/l) 41% (23,556 events) (11,608 events) 47% 26% 21% Moderate-to-Severe Hyperkalemia Epstein M et al. Am J Manag Care. 2015;21:S212-S220

Percent Mortality by Prior RAAS Inhibitor Dose Epstein M et al. Am J Manag Care. 2015;21:S212-S220 40% Maximum Dose Submaximum Dose Discontinued 30% 30.1% 27% % Patients 20% 10% 9.8% 22.4% 20% 13.7% 13.1% 11.0% 10% 8.2% 5.0% 4.1% 0% CKD Stages 3-4 (N = 43,288 total patients across dose categories) Heart Failure (N = 20,529 total patients across dose categories) Diabetes (N = 79,087 total patients across dose categories) Total Population (N = 201,655 total patients across dose categories)

Hyperkalemia in Heart Failure Unmet need for a safe and effective chronic therapy for prevention and treatment of hyperkalemia in HF patients on ACE-I, ARBs, MRA, and ARNI therapies.

New Drugs for Hyperkalemia Patiromer ZS-9 Ca 2+ Gut Lumen K+ Na + Colon Upper/Lower GI

Characteristics of New Potassium Binding Agents Characteristic Patiromer Zirconium Cyclosilicate (ZS-9) GI Absorption Non-absorbable Non-absorbable Molecular structure Organic polymer crystalline inorganic cation exchange compound Mechanism of Action Ca-K exchange Na-K exchange Relative K Affinity - 25-fold > Na Site of Action Colon Upper/Lower GI tract K selectivity relative to SPSS - 120-fold Onset of [K]p lowering 7 hours 2 hours

OPAL-HK Part A: 4-week Treatment Phase (Single-Blind) Subjects with CKD* on RAASi (n=243) Baseline Part A Starting Patiromer Dose 8.4g per day (total daily dose) (n=92) Baseline serum K + 5.1-<5.5 meq/l (Mild Hyperkalemia) 16.8g per day (total daily dose) (n=151) Baseline serum K + 5.5-<6.5 meq/l (Moderate/Severe Hyperkalemia) Primary endpoint: Mean change in serum potassium from Baseline to Week 4 Secondary endpoint: Proportion of patients with serum potassium level of 3.8 meq/l to < 5.1 meq/l at Week 4 Week 4 Part A All patients were on stable dose of at least one RAAS inhibiting agents *estimated glomerular filtration rate 15-60 ml/min/1.73m 2 dose titrated as needed to maintain target serum K+ 3.8 meq/l to < 5.1 meq/l 1. VELTASSA [package insert]. Redwood City, CA. Relypsa, Inc. 2015. 2. Weir M, et al. N Engl J Med. 2015;372(3):211-21.

OPAL-HK Study Part A: Efficacy Results Primary Endpoint: Patiromer Starting Dose Overall Population* Baseline K + [Mean (SD)]: 5.31 meq/l (0.57) (n=90) 5.74 meq/l (0.40) (n=147) 5.58 meq/l (0.51) (n=237) Mild HK Moderate/Severe HK Total Change in Serum Potassium (meq/l) 0-0.2-0.4-0.6-0.8-1 -0.65 (95% CI -0.74, -0.55) -1.01-1.2-1.4-1.23 (95% CI -1.31, -1.16) (95% CI -1.07, -0.95) Weir M, et al. N Engl J Med. 2015;372(3):211-221.

OPAL-HK: Primary and Secondary Efficacy Endpoints Mean Serum K + (meq/l) Study included 243 patients with CKD who were taking a RAAS blocker Secondary Efficacy Endpoint: 76% of subjects had serum K + in the target range (3.8 to <5.1 meq/l) at week 4 Base-line Weir MR, et al. N Engl J Med. 2015;372(3):211-221.

Phase 3 Part B: Exploratory Endpoints 100% P<0.001* P<0.001* Proportion of Subjects (%) 80% 60% 40% 20% 0% 62% 16% Requiring any adjustment of RAASi (ie, down-titration or discontinuation) or patiromer dose increase due to hyperkalemia at any time during Part B 44% 94% Receiving any dose of a RAASi at the end of Part B Placebo Patiromer Weir MR, et al. N Engl J Med. 2015;372(3):211-221.

Mean Change in Serum Potassium Mean (95% CI) Serum Potassium (meq/l) Over 1 Year (AMETHYST-DN) Mean (95% CI) Serum Potassium over 52 weeks N= 301 (start of study) Study Visit (week) Baseline Serum K + 5.0 5.5 meq/l Baseline Serum K + 5.5 6.0 meq/l BL 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52 14 28 Follow-Up (day) N= 173 (study end) Bakris GL, et al. JAMA 2015;314(2):151-161.

Patiromer: Adverse Reactions The most common adverse reactions (incidence 2%) are: Constipation (7.2%) Hypomagnesemia (5.3%) Diarrhea (4.8%) Nausea (2.3%) Abdominal discomfort (2.0%) Flatulence (2.0%) Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with patiromer and included edema of the lips

ZS-9: A Novel First-in-Class Inorganic Crystalline Compound Designed Specifically to Trap K + Adapted from: Stavros F, et al. PLoS One. 2014;9(12):e114686.

In Vitro, ZS-9 is More Selective for Potassium than Kayexalate (SPS) Adapted from: Stravos et al. PLOSONE 2014

ZS-9 Lowers K + in Hyperkalemic Patients Kosiborod M, et al. JAMA. 2014;312(21):2223-2233.

Mean Serum Potassium Levels Over 48 Hours With ZS-9 Serum Potassium Levels During the Open-Label Phase (48 Hours)A, Mean serum potassium levels over time in patients treated during the open-label phase with zirconium cyclosilicate, 10 g, 3 times daily for 48 hours. B, Mean serum potassium levels at 0 and 48 hours across prespecified subgroups of chronic kidney disease (CKD) (by patient history and by estimated glomerular filtration rate [egfr] <60 ml/min/1.73 m 2 ), heart failure, diabetes mellitus, concomitant renin-angiotensin-aldosterone system inhibitor (RAASi) use, and baseline potassium levels. Error bars indicate 95% confidence intervals; shaded region, normal potassium range. Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia: The HARMONIZE Randomized Clinical Trial JAMA. 2014;312(21):2223-2233.

Dose-Dependent Serum K+ Reduction Over 48 Hours in HF Patients on RAASi Source: El-Shahawy M, et al. Oral Presentation During a Late-Breaking Clinical Trial Session at the Heart Failure Society of America (HFSA) 18th Annual Scientific Meeting, Sep 15, 2014,

New Therapies For Hyperkalemia Hyperkalemia is common in patients with HF, CKD and/or diabetes. High levels of potassium may lead to dose reduction or discontinuation of RAAS inhibitors. Current treatments for hyperkalemia have limitations. Both patiromer and ZS-9 are newly available agents that are safe and effective to treat hyperkalemia. Use of these new agents are likely to become important adjuncts to heart failure therapy.